Ivermectin treatment of bancroftian filariasis in Recife, Brazil.
Identifieur interne : 005584 ( PubMed/Corpus ); précédent : 005583; suivant : 005585Ivermectin treatment of bancroftian filariasis in Recife, Brazil.
Auteurs : A D Coutinho ; G. Dreyer ; Z. Medeiros ; E. Lopes ; G. Machado ; E. Galdino ; J A Rizzo ; L D Andrade ; A. Rocha ; I. MouraSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 1994.
English descriptors
- KwdEn :
- Adult, Animals, Brazil, Dose-Response Relationship, Drug, Double-Blind Method, Elephantiasis, Filarial (blood), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (parasitology), Eosinophilia (chemically induced), Fever (chemically induced), Follow-Up Studies, Hematuria (chemically induced), Humans, Ivermectin (administration & dosage), Ivermectin (adverse effects), Ivermectin (pharmacology), Ivermectin (therapeutic use), Kinetics, Liver (drug effects), Liver (physiopathology), Lung (drug effects), Lung (physiopathology), Male, Microfilariae (drug effects), Middle Aged, Military Personnel, Wuchereria bancrofti (drug effects).
- MESH :
- chemical , administration & dosage : Ivermectin.
- chemical , adverse effects : Ivermectin.
- blood : Elephantiasis, Filarial.
- chemically induced : Eosinophilia, Fever, Hematuria.
- drug effects : Liver, Lung, Microfilariae, Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- parasitology : Elephantiasis, Filarial.
- chemical , pharmacology : Ivermectin.
- physiopathology : Liver, Lung.
- chemical , therapeutic use : Ivermectin.
- Adult, Animals, Brazil, Dose-Response Relationship, Drug, Double-Blind Method, Follow-Up Studies, Humans, Kinetics, Male, Middle Aged, Military Personnel.
Abstract
To determine the effectiveness of single oral dosages of ivermectin ranging between 20 and 200 micrograms/kg and to make detailed observations of both the kinetics of parasite killing and the adverse reactions induced by treatment, the present double-blind study on ivermectin treatment of lymphatic filariasis caused by Wuchereria bancrofti was undertaken with 43 microfilaremic patients in Recife, Brazil. Follow-up at one year indicated equivalent efficacy for the 20-, 100-, and 200-micrograms/kg drug dosages in reducing microfilaremia to geometric means of 13-25% of pretreatment levels. Adverse clinical reactions (predominantly fever, headache, weakness, and myalgia) occurred to some degree in almost all patients but generally lasted only 24-48 hr and were easily managed symptomatically. Adverse reactions were significantly milder in those receiving the lowest (20 micrograms/kg) ivermectin dose, and they were significantly correlated with individuals' pretreatment microfilaremia levels in all groups. Posttreatment eosinophilia was a regular feature of the response to treatment, with the magnitude and kinetics also proportional to pretreatment microfilarial levels. Transient pulmonary function abnormalities (16 of 42, 38%), liver enzyme elevations (10 of 43, 23%), and hematuria (9 of 42, 22%) developed posttreatment, but all cleared without significant complications. The results indicate that W. bancrofti from Brazil is similar to strains of the parasites studied elsewhere in susceptibility to ivermectin, that the drug's systemic adverse reactions are essentially those resulting from parasite clearance, and that the intensity of these reactions can be significantly reduced by using the low (20 micrograms/kg) dose of ivermectin. This detailed dose-finding study provides information necessary for developing optimal regimens to treat bancroftian filariasis with ivermectin either alone or in combination with other medications.
PubMed: 8147492
Links to Exploration step
pubmed:8147492Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ivermectin treatment of bancroftian filariasis in Recife, Brazil.</title><author><name sortKey="Coutinho, A D" sort="Coutinho, A D" uniqKey="Coutinho A" first="A D" last="Coutinho">A D Coutinho</name><affiliation><nlm:affiliation>Centro de Pesquisas Aggeu Magalhaes, Fiocruz, Recife, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Dreyer, G" sort="Dreyer, G" uniqKey="Dreyer G" first="G" last="Dreyer">G. Dreyer</name></author><author><name sortKey="Medeiros, Z" sort="Medeiros, Z" uniqKey="Medeiros Z" first="Z" last="Medeiros">Z. Medeiros</name></author><author><name sortKey="Lopes, E" sort="Lopes, E" uniqKey="Lopes E" first="E" last="Lopes">E. Lopes</name></author><author><name sortKey="Machado, G" sort="Machado, G" uniqKey="Machado G" first="G" last="Machado">G. Machado</name></author><author><name sortKey="Galdino, E" sort="Galdino, E" uniqKey="Galdino E" first="E" last="Galdino">E. Galdino</name></author><author><name sortKey="Rizzo, J A" sort="Rizzo, J A" uniqKey="Rizzo J" first="J A" last="Rizzo">J A Rizzo</name></author><author><name sortKey="Andrade, L D" sort="Andrade, L D" uniqKey="Andrade L" first="L D" last="Andrade">L D Andrade</name></author><author><name sortKey="Rocha, A" sort="Rocha, A" uniqKey="Rocha A" first="A" last="Rocha">A. Rocha</name></author><author><name sortKey="Moura, I" sort="Moura, I" uniqKey="Moura I" first="I" last="Moura">I. Moura</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:8147492</idno><idno type="pmid">8147492</idno><idno type="wicri:Area/PubMed/Corpus">005584</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005584</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Ivermectin treatment of bancroftian filariasis in Recife, Brazil.</title><author><name sortKey="Coutinho, A D" sort="Coutinho, A D" uniqKey="Coutinho A" first="A D" last="Coutinho">A D Coutinho</name><affiliation><nlm:affiliation>Centro de Pesquisas Aggeu Magalhaes, Fiocruz, Recife, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Dreyer, G" sort="Dreyer, G" uniqKey="Dreyer G" first="G" last="Dreyer">G. Dreyer</name></author><author><name sortKey="Medeiros, Z" sort="Medeiros, Z" uniqKey="Medeiros Z" first="Z" last="Medeiros">Z. Medeiros</name></author><author><name sortKey="Lopes, E" sort="Lopes, E" uniqKey="Lopes E" first="E" last="Lopes">E. Lopes</name></author><author><name sortKey="Machado, G" sort="Machado, G" uniqKey="Machado G" first="G" last="Machado">G. Machado</name></author><author><name sortKey="Galdino, E" sort="Galdino, E" uniqKey="Galdino E" first="E" last="Galdino">E. Galdino</name></author><author><name sortKey="Rizzo, J A" sort="Rizzo, J A" uniqKey="Rizzo J" first="J A" last="Rizzo">J A Rizzo</name></author><author><name sortKey="Andrade, L D" sort="Andrade, L D" uniqKey="Andrade L" first="L D" last="Andrade">L D Andrade</name></author><author><name sortKey="Rocha, A" sort="Rocha, A" uniqKey="Rocha A" first="A" last="Rocha">A. Rocha</name></author><author><name sortKey="Moura, I" sort="Moura, I" uniqKey="Moura I" first="I" last="Moura">I. Moura</name></author></analytic><series><title level="j">The American journal of tropical medicine and hygiene</title><idno type="ISSN">0002-9637</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Brazil</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Elephantiasis, Filarial (blood)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (parasitology)</term><term>Eosinophilia (chemically induced)</term><term>Fever (chemically induced)</term><term>Follow-Up Studies</term><term>Hematuria (chemically induced)</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (adverse effects)</term><term>Ivermectin (pharmacology)</term><term>Ivermectin (therapeutic use)</term><term>Kinetics</term><term>Liver (drug effects)</term><term>Liver (physiopathology)</term><term>Lung (drug effects)</term><term>Lung (physiopathology)</term><term>Male</term><term>Microfilariae (drug effects)</term><term>Middle Aged</term><term>Military Personnel</term><term>Wuchereria bancrofti (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Eosinophilia</term><term>Fever</term><term>Hematuria</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Liver</term><term>Lung</term><term>Microfilariae</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="parasitology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Liver</term><term>Lung</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ivermectin</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Brazil</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Follow-Up Studies</term><term>Humans</term><term>Kinetics</term><term>Male</term><term>Middle Aged</term><term>Military Personnel</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine the effectiveness of single oral dosages of ivermectin ranging between 20 and 200 micrograms/kg and to make detailed observations of both the kinetics of parasite killing and the adverse reactions induced by treatment, the present double-blind study on ivermectin treatment of lymphatic filariasis caused by Wuchereria bancrofti was undertaken with 43 microfilaremic patients in Recife, Brazil. Follow-up at one year indicated equivalent efficacy for the 20-, 100-, and 200-micrograms/kg drug dosages in reducing microfilaremia to geometric means of 13-25% of pretreatment levels. Adverse clinical reactions (predominantly fever, headache, weakness, and myalgia) occurred to some degree in almost all patients but generally lasted only 24-48 hr and were easily managed symptomatically. Adverse reactions were significantly milder in those receiving the lowest (20 micrograms/kg) ivermectin dose, and they were significantly correlated with individuals' pretreatment microfilaremia levels in all groups. Posttreatment eosinophilia was a regular feature of the response to treatment, with the magnitude and kinetics also proportional to pretreatment microfilarial levels. Transient pulmonary function abnormalities (16 of 42, 38%), liver enzyme elevations (10 of 43, 23%), and hematuria (9 of 42, 22%) developed posttreatment, but all cleared without significant complications. The results indicate that W. bancrofti from Brazil is similar to strains of the parasites studied elsewhere in susceptibility to ivermectin, that the drug's systemic adverse reactions are essentially those resulting from parasite clearance, and that the intensity of these reactions can be significantly reduced by using the low (20 micrograms/kg) dose of ivermectin. This detailed dose-finding study provides information necessary for developing optimal regimens to treat bancroftian filariasis with ivermectin either alone or in combination with other medications.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8147492</PMID><DateCreated><Year>1994</Year><Month>05</Month><Day>05</Day></DateCreated><DateCompleted><Year>1994</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9637</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>3</Issue><PubDate><Year>1994</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of tropical medicine and hygiene</Title><ISOAbbreviation>Am. J. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>Ivermectin treatment of bancroftian filariasis in Recife, Brazil.</ArticleTitle><Pagination><MedlinePgn>339-48</MedlinePgn></Pagination><Abstract><AbstractText>To determine the effectiveness of single oral dosages of ivermectin ranging between 20 and 200 micrograms/kg and to make detailed observations of both the kinetics of parasite killing and the adverse reactions induced by treatment, the present double-blind study on ivermectin treatment of lymphatic filariasis caused by Wuchereria bancrofti was undertaken with 43 microfilaremic patients in Recife, Brazil. Follow-up at one year indicated equivalent efficacy for the 20-, 100-, and 200-micrograms/kg drug dosages in reducing microfilaremia to geometric means of 13-25% of pretreatment levels. Adverse clinical reactions (predominantly fever, headache, weakness, and myalgia) occurred to some degree in almost all patients but generally lasted only 24-48 hr and were easily managed symptomatically. Adverse reactions were significantly milder in those receiving the lowest (20 micrograms/kg) ivermectin dose, and they were significantly correlated with individuals' pretreatment microfilaremia levels in all groups. Posttreatment eosinophilia was a regular feature of the response to treatment, with the magnitude and kinetics also proportional to pretreatment microfilarial levels. Transient pulmonary function abnormalities (16 of 42, 38%), liver enzyme elevations (10 of 43, 23%), and hematuria (9 of 42, 22%) developed posttreatment, but all cleared without significant complications. The results indicate that W. bancrofti from Brazil is similar to strains of the parasites studied elsewhere in susceptibility to ivermectin, that the drug's systemic adverse reactions are essentially those resulting from parasite clearance, and that the intensity of these reactions can be significantly reduced by using the low (20 micrograms/kg) dose of ivermectin. This detailed dose-finding study provides information necessary for developing optimal regimens to treat bancroftian filariasis with ivermectin either alone or in combination with other medications.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Coutinho</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Centro de Pesquisas Aggeu Magalhaes, Fiocruz, Recife, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dreyer</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Medeiros</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Galdino</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>L D</ForeName><Initials>LD</Initials></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Trop Med Hyg</MedlineTA><NlmUniqueID>0370507</NlmUniqueID><ISSNLinking>0002-9637</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004802" MajorTopicYN="N">Eosinophilia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006417" MajorTopicYN="N">Hematuria</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008842" MajorTopicYN="N">Microfilariae</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008889" MajorTopicYN="Y">Military Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8147492</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005584 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 005584 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:8147492
|texte= Ivermectin treatment of bancroftian filariasis in Recife, Brazil.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:8147492" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |